# OnCo record nct04637763 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04637763/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04637763", "NCT04637763" ;
  schema:name "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)"@en ;
  schema:description "A phase 1 trial of Vispacabtagene regedleucel run by Caribou Biosciences, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04637763/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04637763> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/vispacabtagene-regedleucel/> ;
  onco:companies <https://onco.cc/companies/caribou/> .